Minimising nasal bleeding by application of decongestant drops before putting tube through nostrils
Not Applicable
Completed
- Conditions
- Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 172
Inclusion Criteria
Male and female patients of age 18- 65 years with American Society of Anaesthesiologists- Physical Status Grade 1 and 2 posted with indication for nasotracheal intubation i.e. undergoing surgery involving oral cavity, mandible, maxilla, thyroid, neck, difficult airway with decreased mouth opening, cervical spine, etc
Exclusion Criteria
1) Patients who shall not give consent
2) Patients with nasal pathology (septal deviation, turbinate hypertrophy, nasal polyp and trauma)
3) Patients with history of common cold during prior 2 weeks or treatment with nasal decongestants, anti-histamines, NSAIDS
4) Patients with coagulopathy and on anticoagulants
5) Patients with drug allergy, chronic pain syndrome, on analgesic medication
6) Pregnant patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of incidence and severity of epistaxis during fiberoptic-guided nasotracheal intubationTimepoint: At the time of intubation
- Secondary Outcome Measures
Name Time Method 1) Hemodynamic changes following administration of topical vasoconstrictor agents <br/ ><br>2) Patient discomfort, pain and satisfaction scoring 24 hours after extubation <br/ ><br>Timepoint: 1)Hemodynamic changes at time 0 minute, 1 minute, 10 minutes following administration of topical vasoconstrictor agents <br/ ><br>2) Patient discomfort, pain and satisfaction scoring 24 hours after extubation